Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Here's Why Merck Stock Is Down in 2017 Despite a Rising Industry

Shares of Merck (MRK) have declined so far this year compared to an increase witnessed by the industry due to some notable pipeline setbacks.

    Will a 'Huge Tax Cut' Ease Burden for MedTech Players?

    How is the MedTech industry placed in the wake of the current political conundrum surrounding tax reforms?

      JP Morgan Launches US Dividend ETF

      JP Morgan rolls out multi-cap US Dividend ETF.

        J&J Seeks Darzalex's Label Expansion in First-Line Setting

        Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.

          J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen

          J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.

            Quality Dividend ETFs to Tackle Uncertainty

            Consider these 3 dividend ETFs for your portfolio to fight growing market uncertainty.

              United Therapeutics PAH Drug's Exclusivity Period Extended

              United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.

                Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

                Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.

                  J&J Presents Positive New Data for Diabetes Drug Invokana

                  Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.

                    Achillion (ACHN) Shares Down as J&J Announces Stake Sale

                    Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.

                      Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

                      Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

                        Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis

                        CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.

                          AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

                          AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

                            Tirthankar Chakraborty headshot

                            Fretting Over Tax Plan Uncertainty? Buy 5 Ultra-Safe Stocks

                            With the markets apprehending a healthy pullback after a strong run, investing in stocks that are immune to market gyrations seems judicious. The best way to go about doing this is by creating a portfolio of ultra-safe stocks.

                              Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

                              Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.

                                AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View

                                AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.

                                  Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus

                                  Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.

                                    Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

                                    Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.

                                      Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View

                                      Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.

                                        AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up

                                        AbbVie's (ABBV) Q3 earnings surpass estimates with revenues matching the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                                          What's in the Cards for Geron (GERN) this Earnings Season?

                                          With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q3 release.

                                            Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                            Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                              Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y

                                              Anthem's (ANTM) strong third-quarter results were driven by solid enrollment growth.

                                                Is a Beat Likely for Pfizer (PFE) This Earnings Season?

                                                While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q3, genericization of key drugs, pricing pressure and rising competition will hurt sales.

                                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, PayPal, Adobe and Philips

                                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, PayPal, Adobe and Philips